No Safety Concerns Seen With Inclisiran in Large ORION Analy

While there was less MACE with inclisiran, only future outcome trials will determine the drug’s ability to reduce CVD events.

Related Keywords

Baylor College Of Medicine , Texas , United States , Houston , Carl Orringer , Leandro Slipczuk , Abdul Mannan Khan Minhas , R Scott Wright , Christie Ballantyne , Sanofi Regeneron , Alirocumab Praluent , Drug Administration , Novartis , University Of Oxford , Amgen , Journal Of The American College Cardiology , Rooney Heart Institute , Scott Wright , Mayo Clinic , American College , Montefiore Healthcare , Albert Einstein College , Baylor College , Heart Institute ,